Matthew I Milowsky MD
Genitourinary Oncology
Professor of Medicine, Vice Chief of Research, Section Chief, Genitourinary Oncology, Division of Oncology and Co-Director, Urologic Oncology Program, UNC Lineberger Comprehensive Cancer Center
Join to View Full Profile
101 Manning DrChapel Hill, NC 27514
Phone+1 984-974-0000
Fax+1 919-843-6949
Dr. Milowsky is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 1999 - 2002
Tufts Medical CenterResidency, Internal Medicine, 1996 - 1999
State University of New York Downstate Medical Center College of MedicineClass of 1996
Certifications & Licensure
NC State Medical License 2011 - 2026
NY State Medical License 1999 - 2013
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014-2017
- CMS Meaningful Use Stage 1 Certification WebCIS, UNC Health Care, 2012, 2014-2017
Clinical Trials
- Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma Start of enrollment: 2008 Jul 01
- Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
- Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DD GC) In Patients With Muscle-Invasive Bladder Cancer Start of enrollment: 2012 Apr 01
Publications & Presentations
PubMed
- Real-World Outcomes of Patients With Baseline Neuropathy and/or Diabetes Mellitus Receiving Enfortumab Vedotin-Based Regimens for Advanced Urothelial Carcinoma in the ...Albert Jang, Tanya Jindal, Ali Raza Khaki, Cindy Y Jiang, Omar Alhalabi
Clinical Genitourinary Cancer. 2026-01-10 - APOBEC3 promotes squamous differentiation via IL-1A/AP-1 signaling.Michael S Sturdivant, Andrew S Truong, Mi Zhou, Elliott D Toomer, Wolfgang Beckabir
Nature Communications. 2025-12-14 - 1 citationsAdvanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers.Rana R McKay, Sumanta Pal, Wanling Xie, David Aggen, Laurence Albiges
CA. 2025-12-13
Press Mentions
The Society for Immunotherapy of Cancer Announces Late-Breaking Abstracts and Press Briefing Presented at Its 40th Anniversary Annual MeetingOctober 31st, 2025- Bladder Cancer Survival Better with Nivolumab Than Placebo in New AnalysisFebruary 21st, 2025
- Adjuvant Nivolumab Boosts Survival Outcomes in Muscle-Invasive Bladder CancerFebruary 17th, 2025
Grant Support
- UNC Lead Academic Participating SiteUNIV OF NORTH CAROLINA CHAPEL HILL2019–2026
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
